血红蛋白与红细胞分布宽度比值联合血小板与淋巴细胞比值可预测胃癌肝转移患者的生存。

The Ratio of the Hemoglobin to Red Cell Distribution Width Combined with the Ratio of Platelets to Lymphocytes Can Predict the Survival of Patients with Gastric Cancer Liver Metastasis.

机构信息

Department of Gastroenterological Surgery, Harbin Medical University Cancer Hospital, 150 Haping Road, Harbin, Heilongjiang 150081, China.

出版信息

Biomed Res Int. 2021 Jan 9;2021:8729869. doi: 10.1155/2021/8729869. eCollection 2021.

BACKGROUND

Hemoglobin/red cell distribution width (HR) and platelet/lymphocyte (PLR) ratios are considered effective prognostic markers in various cancers. We have proposed a new prognostic parameter: HR+PLR. The aim of this study is to explore the prognostic value of the HR+PLR scoring system in patients with gastric cancer liver metastasis.

METHODS

This study retrospectively analyzed the clinical data of 306 patients with gastric cancer liver metastases admitted to our hospital from 2007 to 2014. According to the size of HR value and PLR value, we will divide the patients into three groups, namely, HR+PLR: (1) 0 points: HR > 1.02 and PLR < 128; (2) 1 point: HR > 1.02 and PLR > 128 and HR < 1.02 and PLR < 128; and (3) 2 points: HR < 1.02 and PLR > 128.

RESULTS

The HR+PLR score was statistically different from age ( = 0.049), T stage ( < 0.001), N stage ( = 0.017), number of liver metastases ( = 0.018), gastrectomy ( < 0.001), hepatectomy ( = 0.001), peritoneal metastasis ( = 0.012), prognostic nutritional index (PNI) ( = 0.028), and neutrophil/lymphocyte ratio (NLR) ( = 0.045). The HR+PLR scoring system has a higher area under the ROC curve (AUC value) than PNI, PLR, HR, and PLR (AUC = 0.798, < 0.001). In multivariate analysis, gastrectomy ( = 0.001), hepatectomy ( < 0.001), chemotherapy ( = 0.014), and HR+PLR score ( < 0.001) were considered independent prognostic factors.

CONCLUSION

For patients with gastric cancer liver metastasis, the HR+PLR score is a simple, reliable, and economic prognostic marker.

背景

血红蛋白/红细胞分布宽度（HR）和血小板/淋巴细胞（PLR）比值被认为是各种癌症的有效预后标志物。我们提出了一种新的预后参数：HR+PLR。本研究旨在探讨 HR+PLR 评分系统在胃癌肝转移患者中的预后价值。

方法

本研究回顾性分析了 2007 年至 2014 年我院收治的 306 例胃癌肝转移患者的临床资料。根据 HR 值和 PLR 值的大小，将患者分为三组，即 HR+PLR：（1）0 分：HR＞1.02，PLR＜128；（2）1 分：HR＞1.02，PLR＞128，HR＜1.02，PLR＜128；（3）2 分：HR＜1.02，PLR＞128。

结果

HR+PLR 评分与年龄（ = 0.049）、T 分期（＜0.001）、N 分期（ = 0.017）、肝转移灶数量（ = 0.018）、胃切除术（＜0.001）、肝切除术（ = 0.001）、腹膜转移（ = 0.012）、预后营养指数（PNI）（ = 0.028）和中性粒细胞/淋巴细胞比值（NLR）（ = 0.045）存在统计学差异。HR+PLR 评分系统的 ROC 曲线下面积（AUC 值）高于 PNI、PLR、HR 和 NLR（AUC = 0.798，＜0.001）。多因素分析显示，胃切除术（ = 0.001）、肝切除术（＜0.001）、化疗（ = 0.014）和 HR+PLR 评分（＜0.001）是独立的预后因素。